MIRAPEX for
Parkinson's Disease
Learn more about how MIRAPEX works.
Click here
Talking to Your
Doctor*
Find out how to help
your doctor help you.
Learn more





*Doctor portrayal

MANAGING PARKINSON'S DISEASE AT EVERY STAGE

References

  • Steece-Collier K, Maries E. Kordower JH. Etiology of Parkinson's disease: genetics and environment revisited [commentary]. PNAS Online US [serial online], October 29, 2002;99(2):13972-13974.
  • Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology. 1967;17:427-442.
  • Martilla RJ, Rinne UK. Epidemiology of Parkinson's disease in Finland. Acta Neurol Scand. 1976;53:81-102.
  • Gibb WRG, Lees AJ. A comparison of clinical and pathological features of young- and old-onset Parkinson's disease. Neurology. 1988;38:1402-1406
  • Martilla RJ, Rinne UK. Epidemiological approaches to the etiology of Parkinson's disease. Acta Neurol Scand. 1989;126:13-18.
  • Parkinson's Disease Foundation. Parkinson's disease: An overview. Available at: http://www.pdf.org/AboutPD. Accessed October 26, 2004.
  • National Institute of Neurological Disorders and Stroke. Parkinson's disease backgrounder. Available at: http://www.ninds.nih.gov/disorders/parkinsons disease/detail parkinsons disease.htm.
  • CNN.com. Michael J. Fox reveals he has Parkinson's disease. Available at: http://www.cnn.com/SHOWBIZ/TV/9811/25/fox.parkinsons/ Accessed November 4, 2004.
  • Waters CH. Diagnosis and Management of Parkinson's Disease. 2nd ed. Caddo, OK: Professional Communications, Inc; 1999.
  • MIRAPEX® (pramipexole dihydrochloride) Prescribing Information.
  • Barone P, Bressman S. Pramipexole without levodopa as early treatment for Parkinson's disease: a long-term follow-up of 717 patients. Poster presented at: 53rd Annual American Academy of Neurology; May 5-11,2001; Philadelphia, Pa.
  • Lieberman A, Ranhosky A, Korts D. Clinical evaluation of pramipexole in advanced Parkinson's disease: results of a double-blind, placebo-controlled, parallel-group study. Neurology. 1997;49:162-168.
  • Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. 1999;66:436-441.
  • Parkinson's disease. Available at: http://www.ecureme.com/emyhealth/data/Parkinson's_Disease.asp. Accessed December 20, 2004.
  • Samii A, Nutt JG, Ransom BR. Parkinson's disease. Lancet. 2004;363:1783-1792.
  • Data on File, Boehringer Ingelheim Pharmaceuticals.
  • Beizer J. Treatment options in Parkinson's disease. American Pharmacy. 1995;NS35(1). 21-31.
  • The Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease. A 4-year randomized controlled trial. Arch Neurol. 2004;61:1044-1053.
  • Pogarell O, Gasser T, van Hilten JJ, et al. Pramipexole in patients with Parkinson's disease and marked drug resistant tremor: a randomised, double-blind, placebo-controlled multicentre study. J Neurol Neurosurg Psychiatry. 2002;72:713-720.
  • National Prescription Audit Plus [basic data report]. IMS Health; 2003:190-193.
  • Mark M, Sage J. Young Parkinson's Handbook. Staten Island, NY: APDA Publications; 2000.
  • Parkinson's disease in the Young. APDA. Available at: http://www.youngparkinsons.org. Accessed February 16, 2005.
  • Giovannini P, Piccolo I, Genitrini S, et al. Early-onset Parkinson's disease. Move Disord. 1991;6(1):36-42.
  • Rezak M. Parkinson's disease in the young. APDA Young Parkinson's Newsletter Summer/Fall 1998:4.
  • Fitzsimmons B, Bunting L. Parkinson's disease: Quality of life issues. J Neurosci Nurs. 1993;28(4):807-817.
  • Brown R, Jahanshahi M, Quinn N, et al. Sexual function in patients with Parkinson's disease and their partners. J Neurol Neurosurg Psychiatry. 1990;3:480-486.
  • Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology. 2001;56(suppl 5):S1-S88.
  • Parlodel® (bromocriptine mesylate) Prescribing Information
  • [Renumbering TK]
  • Requip® (ropinirole) Prescribing Information.
  • Wynalda MA, Wienkers LC. Assessment of potential interactions between dopamine receptor agonists and various human cytochrome P450 enzymes using a simple in vitro inhibition screen. Drug Metab Dispos. 1997;25:1211-1214.
  • Hansten Parkinson's disease. Understanding drug-drug interactions. Science & Medicine. January/February 1998:16-25.
  • Michalets EL. Update: clinically significant cytochrome P-450 drug interactions. Pharmacotherapy. 1998;18:84-112.
  • Lieberman A. 100 questions & answers about Parkinson disease. Sudbury, MA. Jones and Bartlett. 2003.
  • Hauser RA, Lyons KA, Pahwa R, Zesiewicz TA, Golbe LI. Parkinson's Disease Questions and Answers. 4th ed. 2003. West Palm Beach, FL. Merit Publishing International.
  • National Family Caregivers Association (NFCA) Web site. Caregiving Statistics. Available at: http://www.nfcacares.org/who/stats.cfm#1. Accessed November 8, 2004.
 

Important Information about MIRAPEX: MIRAPEX is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD).

MIRAPEX may cause you to fall asleep without any warning, even while doing normal daily activities, such as driving. Before taking MIRAPEX, talk to your doctor if you drink alcohol or take other medications that make you drowsy as these can increase the chance that MIRAPEX will make you feel sleepy or fall asleep when you should be awake. When taking MIRAPEX, hallucinations (seeing, hearing, feeling, or tasting something that isn’t there) may occur and you may sometimes feel dizzy, nauseated, faint or sweaty when you sit up or stand quickly.

In clinical trials for early PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are nausea, dizziness, sleepiness, difficulty falling asleep, involuntary movement, and constipation. In clinical trials for advanced PD, the most commonly reported side effects of MIRAPEX that were more frequent than with placebo are low blood pressure when you sit up or stand quickly, involuntary movement, difficulty falling asleep, dizziness, accidental injury, hallucinations, and dream abnormalities. You should talk with your doctor if you experience these problems.

There have been reports of impulse control disorders and compulsive behaviors in patients taking certain medicines, including MIRAPEX. If you or your family members notice that you are experiencing new or increased gambling urges, increased sexual urges or other intense urges, such as compulsive shopping or eating, while taking MIRAPEX, talk to your doctor.

Please see full Prescribing Information.

This information is intended for U.S. residents only.